VIVA Website Format


VIVA-Asia Rare Tumor Board Webinar

Pediatric NPC

Monday, 22nd January 2024 |  8.00PM - 9.00PM (UTC+8 | SGT)  |  Check your Time Zone


VIVA-ASIA RARE TUMOR BOARD WEBINAR is a virtual quarterly meeting that is organized by VIVA Foundation for Children with Cancer to enable doctors from all over the world to discuss the diagnosis and treatment of rare pediatric tumours.

We're privileged to welcome Dr Hoo Calvin from Hong Kong Children's Hospital and Prof Udo Kontny from RWTH Aachen University, Germany.

Our webinar's focus is on Pediatric NPC, where these esteemed experts will share their invaluable insights and experiences.This is an excellent opportunity to learn from experts in the field and to ask questions about rare tumors. We hope that you will join us for this important meeting.

If you can't make it, you can still register to receive a copy of the webinar recording.

Medical professionals in Singapore may eligible for CME/CPE/CNE credits for attending this webinar.
Credits and Certificates of Attendance will only be issued for those who are able to attend the live session and are in adherence with VIVA's Attendance Policy.


Title: Paediatric NPC

This presentation aims to give an overview of paediatric NPC in Hong Kong over the past 30 years. The epidemiology and long term outcomes including quality of life will be shared during this presentation. We also aim to compare and contrast the difference between children and adolescent NPC with our adult counterparts.

Title: Nasopharyngeal Carcinoma in Children and Adolescents – The GPOH Experience

Pediatric NPC mostly presents as loco-advanced regional disease. Radiotherapy is the key modality for curing patients with NPC. As NPC is a chemosensitive disease, pediatric oncologists have added chemotherapy into its treatment for more than 3 decades. The GPOH has conducted two prospective clinical trials, NPC-91 and NPC 2003, which consisted of induction chemotherapy, radio(chemo)therapy and 6-months of maintenance treatment with interferon-ß. Event-free and overall survival for both trials were >90%. As most cured patients suffer from therapy-related late effects, a major focus on further treatment development will be the reduction of radiation intensity. With the NPC-2003 study, patients with a complete tumor regression after induction chemotherapy have received a reduced radiation dose of 54 Gy instead of 59.4 Gy. In our current trial (NCT06019130), the immune checkpoint-inhibitor Nivolumab is added to induction chemotherapy with cisplatin and 5-fluroruracil, with the aim to increase the percentage of patients with a complete response after induction, thereby allowing to reduce the radiation dose in more patients, and potentially reducing the burden of late effects.



22 Jan 2024 RTB


Prof Kontny Udo

Prof Udo, Kontny

Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Uniklinik RWTH Aachen
Centre for Integrated Oncology (CIO) Aachen, Bonn, Cologne, Düsseldorf
NPC Study Group, German Society of Pediatric Hematology and Oncology (GPOH)





Dr Calvin Hoo

Dr Hoo, Calvin

Resident Specialist, Department of Haematology and Oncology
Hong Kong Children's Hospital
Hong Kong SAR




Prof Godfrey Chan

Prof Chan, Godfrey

Honorary Professor, Department of Paediatrics and Adolescent Medicine
School of Clinical Medicine, The University of Hong Kong
Consultant Paediatric Haematologist Oncologist
Hong Kong Sanatorium and Hospital
Hong Kong SAR



Dr Anthony Liu

Dr Liu, Anthony

Clinical Assistant Professor, Department of Paediatrics & Adolescent Medicine
Hong Kong Children’s Hospital
LKS Faculty of Medicine, The University of Hong Kong
Hong Kong SAR